Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HBB | P68871 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17952317 | 0.91 | MEN1 (0.32) | MEN1KMT2ALMNACYP1A2MAPT | |
| SCHEMBL17952214 | 0.88 | MEN1 (0.31) | MEN1KMT2ALMNACYP1A2MAPT | |
| SCHEMBL17952259 | 0.85 | MAPT (0.34) | MEN1KMT2ALMNACYP1A2MAPT | |
| SCHEMBL17952261 | 0.84 | MEN1 (0.30) | MEN1KMT2AMAPTCASP1TDP1 | |
| SCHEMBL17952275 | 0.84 | KDM4E (0.35) | MEN1KMT2ALMNACYP1A2MAPT | |
| SCHEMBL17952180 | 0.83 | L3MBTL1 (0.39) | MEN1KMT2ALMNACYP1A2MAPT | |
| SCHEMBL17952276 | 0.82 | — | — | |
| SCHEMBL21361142 | 0.82 | — | — | |
| SCHEMBL17952324 | 0.81 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL17952249 | 0.81 | CASP3 (0.38) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10418569-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2019-09-17 | — | — | US | disclosed |
| US-20160218303-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10418569-B2 | Organic electroluminescent materials and devices | OCIAD2, OCIAD1, OSBP2 | MEN1 4476/4885KMT2A 3749/4885LMNA 2707/4885 |
| US-20160218303-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OCIAD1, OSBP2 | MEN1 4476/4885KMT2A 3749/4885LMNA 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.